News und Analysen
![Never Will I Ever Buy Preclinical Biotech Stocks. No Way!](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Never Will I Ever Buy Preclinical Biotech Stocks. No Way!
![Can Bellicum Pharmaceuticals Stock Bounce Back?](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Can Bellicum Pharmaceuticals Stock Bounce Back?
![Biogen: Diese Preisgestaltung könnte sich als Bumerang entpuppen!](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Biogen: Diese Preisgestaltung könnte sich als Bumerang entpuppen!
![Ariad Pharmaceuticals setzt neue REKORDE!](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Ariad Pharmaceuticals setzt neue REKORDE!
![Ariad: Sind das gute oder schlechte Neuigkeiten?](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Ariad: Sind das gute oder schlechte Neuigkeiten?
![TESARO Initiates Phase 3 Trial of Niraparib for Treatment of Patients With Ovarian Cancer](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
TESARO Initiates Phase 3 Trial of Niraparib for Treatment of Patients With Ovarian Cancer
![Exelixis (EXEL) Q2 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Exelixis (EXEL) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q2 2024 Earnings CallAug 06, 2024, 5:00 p.m. ET
Operator
Source Fool.com
![Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?: https://g.foolcdn.com/editorial/images/776121/physician-talking-to-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWFXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--99d8196e52f82ce755c490f9294c8fe48441668b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-talking-to-patient.jpg?locale=de)
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Many billionaire investors are going all in on artificial intelligence (AI). That's understandable. AI is quickly being integrated into businesses' day-to-day operations. The leaders in the field
![Exelixis (EXEL) Q1 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Exelixis (EXEL) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q1 2024 Earnings CallApr 30, 2024, 5:00 p.m. ET
Operator
Source Fool.com
![Why NovoCure Stock Soared 18.3% This Week: https://g.foolcdn.com/editorial/images/770931/research-scientists-drugs-pharma-biotech.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFJsYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6e523b7b4286ad554918856738856096e733ee9b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/research-scientists-drugs-pharma-biotech.jpg?locale=de)
Why NovoCure Stock Soared 18.3% This Week
Shares of Novocure (NASDAQ: NVCR) jumped 18.3% this week, according to data from S&P Global Market Intelligence, after the company announced encouraging results from a phase 3 study of its Tumor
![Why Novocure Stock Is Jumping Today: https://g.foolcdn.com/editorial/images/770997/novocure-person-with-ttfields-on-head.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL2xqYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b08c713288bee75db112b334c597f778a206da74/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/novocure-person-with-ttfields-on-head.jpg?locale=de)
Why Novocure Stock Is Jumping Today
Shares of Novocure (NASDAQ: NVCR) were jumping 6.3% higher as of 11:15 a.m. ET on Thursday after rising as much as 9.2% earlier in the day. The nice gain came after the company announced results
![2 Stocks Under $30 to Buy and Hold: https://g.foolcdn.com/editorial/images/765350/doctor-and-patient-in-a-hospital-room.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMEUzYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5daea28d9de89001ff39b078fa9e748cf34be696/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-and-patient-in-a-hospital-room.jpg?locale=de)
2 Stocks Under $30 to Buy and Hold
What is a reasonable sum of money to start investing in stocks? $10,000? $1,000? $500? The truth is, thanks to online brokers who now offer trades at low or no fees and fractional shares, investors
![Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited: https://g.foolcdn.com/editorial/images/764217/clean-room-in-pharmaceutical-factory-with-technician.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMkV1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6b95a40938e61248b93fea3debd638d81a03e05f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/clean-room-in-pharmaceutical-factory-with-technician.jpg?locale=de)
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
Danish pharmaceutical company Novo Nordisk (NYSE: NVO) just made the headlines for something other than Ozempic. Well, sort of. One of the company's subsidiaries, Novo Holdings, is responsible for
![Exelixis (EXEL) Q4 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q4 2023 Earnings CallFeb 06, 2024, 5:00 p.m. ET
Operator
Source Fool.com
![Why Catalent Stock Soared Today: https://g.foolcdn.com/editorial/images/764078/research-scientists-drugs-pharma-biotech-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUVvYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2461597cdf8e6ee975059c8c172bef021e10684c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/research-scientists-drugs-pharma-biotech-1.jpg?locale=de)
Why Catalent Stock Soared Today
Shares of Catalent (NYSE: CTLT) rose by 9.7% on Monday after the pharmaceutical contract manufacturing and drug delivery technology specialist agreed to be acquired by Novo Holdings, the parent
![Why Novo Nordisk Stock Crushed the Market on Monday: https://g.foolcdn.com/editorial/images/764093/stethescope-atop-us-currency-and-coins.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVVvYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--296f0d25a196c5fa6a5d9c39bd2a6f92872e0764/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/stethescope-atop-us-currency-and-coins.jpg?locale=de)
Why Novo Nordisk Stock Crushed the Market on Monday
A major acquisition by its controlling shareholder pushed Novo Nordisk's (NYSE: NVO) U.S.-listed shares 4% higher on Monday. As a result of the deal, Novo Nordisk will acquire from that shareholder
![Is Invitae Stock a Buy Now?: https://g.foolcdn.com/editorial/images/762971/gettyimages-1072035598.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOWdaYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d047e303694c7149834d61f7b565ac195e70ee2b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1072035598.jpg?locale=de)
Is Invitae Stock a Buy Now?
Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to
![Invitae (NVTA) Q3 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Invitae (NVTA) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Invitae (NYSE: NVTA)Q3 2023 Earnings CallNov 08, 2023, 4:30 p.m. ET
Operator
Source Fool.com
![Why Sage Therapeutics Stock Sank Today: https://g.foolcdn.com/editorial/images/754213/medical-professional-with-hand-on-head.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFRNYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0ea59ffb000822cc58ce9f6c1959e7561133826e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/medical-professional-with-hand-on-head.jpg?locale=de)
Why Sage Therapeutics Stock Sank Today
It wasn't a wise move for investors to hold or buy Sage Therapeutics (NASDAQ: SAGE) shares on Tuesday. Its price tumbled by nearly 5% as the market digested the healthcare company's third-quarter
![3 Things About Invitae Every Smart Investor Knows: https://g.foolcdn.com/editorial/images/753343/researcher-loads-diagnostic-analyzer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1hKYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d134d492b72892a27625809bbc159ff532e662a3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/researcher-loads-diagnostic-analyzer.jpg?locale=de)
3 Things About Invitae Every Smart Investor Knows
Genetic-testing company, Invitae (NYSE: NVTA), isn't as easy to understand as it might seem. After more than a year of pivoting and scaling down its operations, changing its leadership, and
![Is Novocure Stock a Buy?: https://g.foolcdn.com/editorial/images/752915/cancer-patient-flexing-muscle.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0xIYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ad8f30cb36b2f2c8d8edd75d783fe323455717b9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/cancer-patient-flexing-muscle.jpg?locale=de)
Is Novocure Stock a Buy?
Cancer is one of the leading causes of death worldwide. That's why dozens of healthcare companies are constantly seeking new ways to treat, diagnose, or prevent it.
Medical device specialist
![Exelixis (EXEL) Q3 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Exelixis (EXEL) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q3 2023 Earnings CallNov 01, 2023, 5:00 p.m. ET
Operator
Source Fool.com
![Is Invitae Stock a Buy Now?: https://g.foolcdn.com/editorial/images/753071/gettyimages-1059661940.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNWJEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8ede30e6a210e7e056871eede90ed7b3bb138bf9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1059661940.jpg?locale=de)
Is Invitae Stock a Buy Now?
Invitae (NYSE: NVTA) recently announced news that made its shares pop. The genetic testing company won a regulatory nod for a first-of-its-kind test for hereditary cancer risk. The U.S. Food and
![Why Blueprint Medicines Stock Soared Today: https://g.foolcdn.com/editorial/images/752482/doctors-office-medical-equipment-brightly-colored.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN0MrYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d8de35312a016972a630be10907d1defa49214da/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctors-office-medical-equipment-brightly-colored.jpg?locale=de)
Why Blueprint Medicines Stock Soared Today
Shares of Blueprint Medicines (NASDAQ: BPMC) closed up 25.6% on Thursday after the cancer and blood discorder therapy company announced stronger-than-expected quarterly results.
Blueprint Medicines'
![Why Novocure Stock Was Sick Today: https://g.foolcdn.com/editorial/images/752492/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN20rYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4ec047260680f0be2b42d9c0b6937d4b0c341b7e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg?locale=de)
Why Novocure Stock Was Sick Today
Oncology-focused healthcare company Novocure (NASDAQ: NVCR) wasn't much of a cure for anyone's ill finances on Thursday. Its share price dived by nearly 8% on the day after management released its